Interestingly, another recent study showed that bortezomib could inhibit the downstream signaling of indoleamine 2,3-dioxygenase, a major inducer of immune tolerance during tumor development, through suppression of signal transducer and activator of transcription 1 (STAT1) in NPC cells [78]. This evidence concerns the gene STAT1 and nasopharyngeal carcinoma.